Why the Medical Developments share price charged higher in October

Find out why the Medical Developments International Ltd (ASX: MVP) share price charged 17.7% higher as one of the October ASX winners.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Medical Developments International Ltd (ASX: MVP) share price was one of the big gainers on the ASX last month.

The Aussie medical devices group had a huge month amid announcing a new CSIRO deal and several strong Penthrox updates.

Why did the Medical Developments share price charge higher?

The Medical Developments share price charged 17.7% higher to $5.85 per share by month-end. The big gains came in mid-October as the company updated the market on its Penthrox product.

Penthrox is an analgesic used by GPs, military forces and similar for emergency pain relief. It's commonly known as the "green whistle" due to the appearance of its hand-held inhaler.

The biggest boost for the Medical Developments share price came on 22 October after a key product update. The company's shares charged higher after Medical Developments reported strong Penthrox results from its European studies.

Just a day later on October 23, the Aussie company launched its signature product in Italy – the latest in a string of milestones.

This also triggered a US$2 million (A$2.9 million) payment from development partner Mundipharma which is expected in 2020.

In late October the company also signed a new Manufacturing Development Project with the CSIRO after 18 years of partnership. Medical Developments will invest up to $5 million over 5 years to develop new manufacturing technologies for pharmaceutical products.

Is November the time to buy?

The Medical Developments share price has outperformed the ASX 200 so far in 2019 after surging 39.44% higher.

The big red flag for me is just how expensive the company's shares are for what you're getting back in earnings.

The Medical Developments price-to-earnings (P/E) ratio is an astonishing 371x earnings, although these metrics can be flawed for growth companies.

Medical Developments has seen solid growth for the last 5 years as its shares have surged 371.43% to $5.94 per share.

However, I think I'd prefer to invest in a blue-chip name like CSL Ltd (ASX: CSL) given where we're at in the cycle right now.

Kenneth Hall has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Medical Developments International Limited. The Motley Fool Australia has recommended Medical Developments International Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

A man sits in despair at his computer with his hands either side of his head, staring into the screen with a pained and anguished look on his face, in a home office setting.
Share Fallers

Why EML, GQG Partners, IGO, and Integrated Research shares are sinking today

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a strong gain. At the time of…

Read more »

Man drawing an upward line on a bar graph symbolising a rising share price.
Share Gainers

Why EOS, News Corp, Polynovo, and Pro Medicus shares are roaring higher today

These shares are starting the week positively. But why?

Read more »

A couple stares at the tv in shock, one holding the remote up ready to press.
Mergers & Acquisitions

Telstra share price climbs amid $3.4b Foxtel sale

Who is buying the Foxtel business? Let's find out.

Read more »

A young man pointing up looking amazed, indicating a surging share price movement for an ASX company
Share Market News

Brokers say these ASX 200 growth stocks could rise 50% to 70%

Analysts think these shares could be dirt cheap and destined to generate big returns.

Read more »

Two people having a meeting using a laptop and tablet to discuss Seven West Media's balance sheet
Broker Notes

Why these ASX shares could be top SMSF options in 2025

Analysts are bullish on these high-quality shares. Let's find out why.

Read more »

The words short selling in red against a black background
Share Market News

These are the 10 most shorted ASX shares

Let's see which shares short sellers are targeting this week.

Read more »

Smiling man with phone in wheelchair watching stocks and trends on computer
Share Market News

5 things to watch on the ASX 200 on Monday

A good start to the week is expected for Aussie investors. Here's what to watch.

Read more »

A businessman compares the growth trajectory of property versus shares.
Opinions

What's the outlook for shares vs. property in 2025?

The experts have put out their new year predictions...

Read more »